Glimepiride/Rosiglitazone Maleate

格列美脲/马来酸罗格列酮

Report date: 2026/05/26 20:00:28

Base Information

Drug NameGlimepiride/Rosiglitazone Maleate
Drug Alias Name马来酸罗格列酮/格列美脲Rosiglitazone Maleate/Glimepiride格列美脲+罗格列酮rosiglitazone maleate and glimepirideglimepiride and rosiglitazone maleate +[7] 
ClassificationSmall molecules
Mechanisms of ActionKATP channels blockersSulfonylurea receptor modulatorsPeroxisome proliferator-activated receptor γ agonists
TargetsSulfonylurea receptorPeroxisome proliferator-activated receptor γKATP channels
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2005/11/23
Country/TerritoryUnited StatesEU
CombinationsYes Rosiglitazone MaleateGlimepiride
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcSb Pharmco Puerto Rico IncSmithkline Beecham Ltd
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeA10BD04
Related LinksKEGG